TP53 and neoplasm: However, 17p deletions or TP53 aberrations are strongly associated with treatment resistance, including to ibrutinib, and patients with blastoid morphology, a high tumor proliferation index, and disease progression within 24 months have exhibited adverse outcomes with ibrutinib monotherapy or ibrutinib-containing combination therapy [20–22].